Feature | June 10, 2014

Opti-SPECT/PET/CT: Five Different Imaging Systems Now Combined

Wide range of molecular imaging modalities is at researchers’ fingertips with a hybrid device dedicated for early-stage clinical trials

June 10, 2014 – Taking their pick, biomedical researchers can now conduct five different imaging studies in one scan with a state-of-the-art preclinical molecular imaging system that scientists unveiled during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.


The imaging device allows single photon emission tomography (SPECT), positron emission tomography (PET), X-ray computed tomography (CT), fluorescence and bioluminescence imaging — powerful imaging techniques that provide different information about anatomy and physiological processes happening within the body. With the Opti-SPECT/PET/CT system, SPECT or PET information details drug distribution and improves interpretation of optical data, while bioluminescence and fluorescence characterize additional tumor properties.  The tracers that are developed with the system will be used as a surgical guide for clinicians.


“We need to know as much as possible from our enemy: the tumor,” Frederik Beekman, Ph.D., explained.  Beekman is head of radiation technology and medical imaging and a professor at Delft University of Technology in Delft, The Netherlands. “This research proves that we can now obtain comprehensive data from five medical imaging systems in a single scan. It is minimally invasive and requires only a single dose of anesthesia.”


Opti-SPECT/PET/CT is built on a small scale for preclinical studies and allows scientists to use a gamut of imaging methods including high resolution nuclear medicine (SPECT and PET), radiological (CT) and optical imaging (fluorescence and bioluminescence). This means that information about organ function, structure and real-time physiological signals revealed within the light spectrum are all available in a synergistic fusion of advanced medical imaging. The hybrid system includes high-performance cameras and an on-board dark room. The molecular imaging platform could be used for new drug discovery, especially for imaging agents that could be used intraoperatively for patients undergoing cancer surgery.


To test the device, researchers imaged models and then mice in multiple studies using a fluorescent dye optical agent and a nuclear medicine imaging agent that combines a radioactive particle with a chemical drug compound. The agent is injected and then imaged as it homes in on and interacts with specific bodily functions. In this case, that function is angiogenesis, or the development of new blood vessels, which often proliferate as a tumor grows. Results of the study confirmed the imaging system’s functionality and proved that it was comparable to other add-on imaging platforms for preclinical studies.


For more information: www.snmmi.org


Related Content

Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
Guerbet, acquisition, Mallinckrodt, CMDS business, contrast media, CT, MRI
News | Contrast Media| July 29, 2015
Guerbet announced that it has entered into a definitive agreement under which it will acquire Mallinckrodt's contrast...
Vital Images, Toshiba, CT Myocardial Perfusion, cardiac CT, CORE 320 study
Technology | July 15, 2015
Vital Images Inc. will debut its U.S. Food and Drug Administration (FDA) 510(k)-cleared CT Myocardial Perfusion...
SHAPE, coronary artery calcium, USPSTF, heart attack risk
News | Computed Tomography (CT)| July 08, 2015
The Society for Heart Attack Prevention and Eradication (SHAPE) submitted a letter to the U.S. Preventive Services Task...
Toshiba CT

PinnacleHealth selected Toshiba as its imaging systems vendor because of its quality and to help reduce imaging radiation dose to improve patient safety.

Sponsored Content | Case Study | Radiation Dose Management| July 07, 2015
Safety accidents drive up costs, damage reputations and lower patient satisfaction scores. For instance, if a patient...
Medraysintell, nuclear medicine, World Market Report, radiopharmaceuticals
News | Nuclear Imaging| July 06, 2015
Medraysintell released its updated World Market Report and Directory on Nuclear Medicine, Edition 2015, in late June,...
osteoporosis, heart disease, linked, older people, Southampton MRC, CT
News | Cardiac Diagnostics| July 02, 2015
University of Southampton scientists have discovered a link between coronary heart disease and osteoporosis, suggesting...
radiation exposure, CT, X-ray, cancer, James Welsh, Jeffry Siegel, Loyola
Feature | Radiation Dose Management| July 01, 2015
In recent years, there has been widespread media coverage of studies purporting to show that radiation from X-rays,...
nuclear medicine diagnostic market, North America, PET, SPECT, Mordor
News | Nuclear Imaging| June 29, 2015
The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for...
Siemens, MES contract, William Osler Health System, Ontario, Canada
News | Cardiac Imaging| June 26, 2015
Canadian hospital William Osler Health System (Osler), based in Ontario, has awarded Siemens Healthcare a Managed...
Overlay Init